OGN Q3 2025

Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Organon navigated a turbulent third quarter under interim leadership, reporting Q3 2025 revenue of $1.60 billion and earnings per share of $1.01 as the women's health and pharmaceutical company managed through a leadership transition tied to an Audit… Read more Organon navigated a turbulent third quarter under interim leadership, reporting Q3 2025 revenue of $1.60 billion and earnings per share of $1.01 as the women's health and pharmaceutical company managed through a leadership transition tied to an Audit Committee investigation into its wholesaler sales practices. The standout performer was the Biosimilars franchise, which grew 19% driven by strong Hadlima uptake and favorable tender timing, though that momentum was offset by a 9% ex-FX decline in Nexplanon, the company's largest single product, as reduced U.S. Government program funding weighed on demand. GAAP gross margin contracted to 53.5% from 58.3% a year ago due to one-time manufacturing costs, while adjusted EBITDA margin expanded to 32.3% from 29.0%, reflecting a 14% reduction in non-GAAP operating expenses. Looking ahead, Organon trimmed its full-year 2025 revenue guidance to $6.20 billion–$6.25 billion and narrowed adjusted EBITDA margin guidance to approximately 31.0%, while a planned divestiture of the Jada system for up to $465 million signals a strategic pivot toward reducing debt and refocusing the portfolio.